Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa.
HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Result: PR20 shows an expanded inhibitor binding cavity due to a cluster of mutations (D30N, V32I, I47V, and I84V).
Result: Another study on single mutants V32I, L33F, L76V, and L90M showed how remote mutations can impact inhibitor binding by altering protein ensemble dynamics through a rearranged network of residues circulating to the active site.
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
PMID: 31430369
2019
The Journal of antimicrobial chemotherapy
Method: Primary PI-R substitutions were D30N, V32I, M46I/L, I47V/A, G48V, I50V/L, I54M/L, Q58E, T74P, L76V, V82A/F/L/S/T, N83D, I84V, N88S and L90M in PR.
Table: V32I
Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population.
Result: The next most common SDRMs, V32I, I50V/L, L76V, and I84V, each occurred in <=5 individuals.
Structural studies of antiviral inhibitor with HIV-1 protease bearing drug resistant substitutions of V32I, I47V and V82I.
PMID: 31092330
2019
Biochemical and biophysical research communications
Method: The cl
Discussion: Overall, the loss of internal contacts among flap residues and disruption of the ion pair between Arg8 and Asp29' are consistent with molecular dynamics simulations suggesting substitutions V32I, I47V and V82I in HIV-2 PR decrease the hydrophobic interactions with APV and DRV.
Discussion: This new structure of PRTri/1 suggests how drug resistant mutations of V32I and I47V on opposite sides of the S2 and S2' subsites can partially compensate for altered hydrophobic interactions with inhibitors and other protease residues, while mutation V82I induces alternate conformations of Arg8/8' and introduces new interactions with Leu10 and the P2 group of 1.
Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence.
Abstract: Compared to rHIVWT, rHIVV32I was highly susceptible to DRV and had significantly reduced fitness, explaining why V32I did not emerge upon selection of rHIVWT with DRV.
Abstract: Here, we show that the preexistence of certain single amino acid substitutions such as V32I, I54M, A71V, and I84V in HIV-1 protease facilitates the development of high-level DRV resistance.
Abstract: However, wild-type HIVNL4-3 (rHIVWT) failed to acquire V32I and did not develop DRV resistance.
Abstract: Interestingly, all in vitro-selected highly DRV-resistant HIV-1 variants acquired V32I but never emerged in wild-type HIV (HIVWT), and V32I itself rendered HIV-1 more sensitive to DR